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Introduction {#ccr31172-sec-0001}
============

Macrophage activating syndrome is also called hemophagocytic syndrome (HPS). It may be primary as in familial hemophagocytic lymphohistiocytosis (HLH), Chediak--Higashi, Griscelli, and Purtilo syndromes, or secondary as in case of malignancies hemato‐oncology, oncologic diseases, infectious diseases, or autoimmune disease. HPS is rare but underdiagnosed and can be life‐threatening if undiagnosed. Its incidence is estimated between 0.8% and 4% cases per year including pediatric and adult HPS [1](#ccr31172-bib-0001){ref-type="ref"}.

Hemophagocytic syndrome is known since the 1950s, and further described by Risdall et al. [2](#ccr31172-bib-0002){ref-type="ref"}. The pathophysiology consists of activation of T lymphocytes and natural killer cells (HLH), either secondary to an opportunistic infection, or primary due to a deficiency of immunomodulatory mechanisms.

This HLH immune activation leads to a high production of pro‐inflammatory cytokines. These cytokines activate the monocyte--macrophage system and enhance the HLH in a positive feedback [3](#ccr31172-bib-0003){ref-type="ref"}, [4](#ccr31172-bib-0004){ref-type="ref"}, [5](#ccr31172-bib-0005){ref-type="ref"}, [6](#ccr31172-bib-0006){ref-type="ref"}, [7](#ccr31172-bib-0007){ref-type="ref"}.

These macrophages are responsible for hemophagocytosis expressed clinically by various symptoms such as fever, lymphadenopathy, hepatosplenomegaly. Clinical presentation of these signs strongly suggests HPS.

Hemophagocytic syndrome occurrence in pregnancy is rare and there are only a few reported cases in the literature [5](#ccr31172-bib-0005){ref-type="ref"}, [8](#ccr31172-bib-0008){ref-type="ref"}, [9](#ccr31172-bib-0009){ref-type="ref"}, [10](#ccr31172-bib-0010){ref-type="ref"}, [11](#ccr31172-bib-0011){ref-type="ref"}, [12](#ccr31172-bib-0012){ref-type="ref"}, [13](#ccr31172-bib-0013){ref-type="ref"}, [14](#ccr31172-bib-0014){ref-type="ref"}, [15](#ccr31172-bib-0015){ref-type="ref"}, [16](#ccr31172-bib-0016){ref-type="ref"}, [17](#ccr31172-bib-0017){ref-type="ref"}, [18](#ccr31172-bib-0018){ref-type="ref"}, [19](#ccr31172-bib-0019){ref-type="ref"}. Here, we describe a case of HPS during the third trimester (30 weeks of gestational age (GA)) of pregnancy: its diagnosis, treatment, and fetal and maternal outcomes. This case is further compared with the literature to set forth a proposal for advancement of best clinical practices in HPS during pregnancy.

Methods {#ccr31172-sec-0002}
=======

We present here the case of a primigravida 44‐year‐old woman who presented at 30 weeks GA + 4 days to the emergency room for fever of 39.4°C associated with a cough since 15 days. This patient had a history of primary infertility salpingectomy for hydrosalpinx. Raynaud syndrome with positive antinuclear antibodies (e.g., antiribonucleoproteins) and moderate peripheral thrombocytopenia have been diagnosed since 2 years. Antiphospholipid antibodies were negative. The pregnancy was achieved by in vitro fertilization with oocyte donation. Despite abnormal (i.e., dark circles on the legs and arms) skin pigmentation early in pregnancy, the diagnosis of lupus (i.e., before pregnancy onset, she has been followed up for thrombocytopenia and suspicion of autoimmune disease) or Sharp syndrome (mixed connective tissue disease) could not be confirmed. Nevertheless, given the suspicion of autoimmune disease, aspirin 75 mg/day was started.

At the emergency room, the patient presented with fever of 39.4°C, blood pressure at 99/62 mmHg, heart rate at 121/min, and oxygen saturation at 98% on room air. There was no history of infection or recent travel. The chest radiography showed some pulmonary infiltrates. Other clinical examinations were normal except for the presence of submandibular adenopathy. Blood biology workup showed moderate pancytopenia and inflammatory syndrome (Table [1](#ccr31172-tbl-0001){ref-type="table-wrap"}). The fetal heart rate recording showed tachycardia (i.e., due to the high fever, 170 beats per min). As a result, the patient was hospitalized in gynecology--obstetrics unit (Fig. [1](#ccr31172-fig-0001){ref-type="fig"}). Intravenous antibiotic (amoxicillin 1 g tid) was started and the baseline laboratory workups (urinary and blood bacteriological analyses) were negative.

###### 

Laboratory trends from baseline to Day 9

                                     D0     D2     D3     D4      D9
  ---------------------------------- ------ ------ ------ ------- ------
  Temperature (°C)                   39.4   38.2   --     36.1    37
  Hemoglobin (g/dL)                  8.4    8.6    9.3    7.9     9
  Platelets (Giga/L)                 130    107    103    85      74
  Leukocytes (Giga/L)                3.4    2      2.1    --      3.1
  Lymphocytes (Giga/L)               --     0.37   0.58   --      0.73
  Polynuclear neutrophils (Giga/L)   --     1.42   1.3    0.6     2.11
  C‐reactive Protein (mg/L)          64     90.6   121    160     47
  ALAT (UI/L)                        --     --     --     51      --
  ASAT (UI/L)                        --     --     --     106     --
  Haptoglobin (g/L)                  --     --     --     \<0.1   --
  LDH (UI/L)                         --     --     --     1520    --
  Fibrinogen (g/L)                   4.45   4.45   4.89   4.89    --
  Cephalin clotting time             --     --     --     1.34    --
  Kaolin clotting time               --     --     --     1.16    --
  Triglyceridemia (mg/dL)            --     --     --     2.85    --
  Ferritinemia (*μ*g/L)              --     --     --     1373    498
  Potassium (mmol/L)                 --     --     --     3.4     --
  Proteinuria (g/L)                  --     --     --     0.45    --
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Within a few hours of antimicrobial therapy, there was an improvement of pulmonary symptoms, yet a deterioration of pancytopenia.

Upon patient\'s arrival to the internal medicine unit, a bi‐antimicrobial therapy with azithromycin and amoxicillin was started. After 48 h of treatment, new biological deteriorations were observed (Table [1](#ccr31172-tbl-0001){ref-type="table-wrap"}): moderate hepatic cytolysis, cholestasis, hemolysis, low potassium, hypertriglyceridemia, hyperferritinemia, inflammatory syndrome, elevated proteinuria (with normal blood pressure), and deterioration of pancytopenia.

Additional laboratory workup in search for antinuclear antibodies showed very slight amount (one positive antinuclear antibodies reading out of 320). All infectious explorations were negative (blood culture, cytobacteriological examination of urine, parvovirus B 19 serology, and PCR, searching for pneumococcus, legionella, mycoplasma pneumoniae, and chlamydiae, EBV, HCV, TPHA, and VDRL, and HIV serology, and tuberculosis). The patient had immunity against CMV, rubella, and toxoplasmosis.

Deterioration of liver function warranted an abdominal ultrasound which showed isolated and moderate hepatomegaly.

Hemophagocytic syndrome was suspected given the clinicobiological characteristics associating fever, hepatomegaly, pancytopenia, hyperferritinemia, and hypertriglyceridemia. This diagnosis was promptly confirmed by myelogram (Fig. [2](#ccr31172-fig-0002){ref-type="fig"}).
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The myelogram did not show abnormal cells such as Sternberg, or osteoblasts, or osteoclasts. Given the HPS confirmation, parenteral glucocorticosteroids (GC) were started (methylprednisolone at 1 mg/kg). Maturation of fetal lungs was achieved. At the same time, antibiotic spectrum was again enlarged and amoxicillin was replaced with cefotaxime. The clinical and biological evolution became promptly satisfactory. Thromboprophylaxis was started.

In obstetric terms, fetal ultrasound monitoring showed intrauterine growth restriction below the 3rd percentile (i.e., fetal weight: 1548 g at 32 GA + 3 days), with normal fetal and maternal vascular ultrasound. At 38 GA + 4 days, because of the low weight for intrauterine growth restriction (i.e. 2258 g ± 15%), gestational diabetes, and detected oligohydramnios, it was decided to induce labor. The patient gave birth at 38 GA + 6 days, to a girl weighing 2380 g (1st percentile) and in good health.

During the postpartum, oral GC prednisolone was continued for 4 weeks at the dosage of 60 mg per day. A decrease in dosage was scheduled at 3 months postpartum. No HPS relapse occurred after discontinuation of GC and no new autoimmune disease symptoms were found during follow‐up. The newborn\'s 8‐month clinical examination showed a normal growth without any sign of neurological damage.

Results {#ccr31172-sec-0003}
=======

Tables [2](#ccr31172-tbl-0002){ref-type="table-wrap"} and [3](#ccr31172-tbl-0003){ref-type="table-wrap"} display the review of HPS peri‐pregnancy data from the literature and our work.

###### 

Displays the results of the comparison between our case and the related literature (first part)

  Authors/\[biblio\]                                                     Gestational age (weeks)   Maternal age (years)   Known risk factors                                                 Prepartum complications                                                 Clinical signs                    Laboratory work up                                                   HPS etiology                    Study year
  ---------------------------------------------------------------------- ------------------------- ---------------------- ------------------------------------------------------------------ ----------------------------------------------------------------------- --------------------------------- -------------------------------------------------------------------- ------------------------------- ------------
  Gill et al. [11](#ccr31172-bib-0011){ref-type="ref"}                   18                        30                     No                                                                 Non                                                                     Fever, hepatomegaly               Pancytopenia, cytolysis                                              Unclear                         1994
  Mihara et al. [10](#ccr31172-bib-0010){ref-type="ref"}                 16                        32                     No                                                                 Non                                                                     Fever                             Pancytopenia, hyperferritinemia, markedly elevated LDH               EBV                             1999
  Nakabayashi et al. [13](#ccr31172-bib-0013){ref-type="ref"}            21                        ND                     No                                                                 Preeclampsia, DIVC, IUGR                                                Fever                             Thrombopenia, leukopenia, cytolysis                                  Unclear                         1999
  Chmait et al. [9](#ccr31172-bib-0009){ref-type="ref"}                  29                        24                     No                                                                 DIVC                                                                    Adenopathy, fever                 Pancytopenia, cytolysis                                              EBV (postmortem diagnosis)      2000
  Yamagushi et al. [17](#ccr31172-bib-0017){ref-type="ref"}              2nd trimester             ND                     No                                                                 No                                                                      Fever, skin lesions               Pancytopenia, hypertriglycemia, hyperferritinemia, cytolysis         HSV                             2005
  Pérard et al. [12](#ccr31172-bib-0012){ref-type="ref"}                 22                        28                     Lupus                                                              Preeclampsia                                                            Fever                             Pancytopenia, hypertriglycemia, hyperferritinemia                    Lupus                           2007
  Hahaoka et al. [27](#ccr31172-bib-0027){ref-type="ref"}                23                        33                     No                                                                 Lymphoma diagnosed                                                      Fever, hepatosplenomegaly         Pancytopenia                                                         B‐cell Lymphoma                 2007
  Teng et al. [8](#ccr31172-bib-0008){ref-type="ref"}                    23                        28                     No                                                                 Transfusion for anemia compensation and dyspnea improvement             Fever, hepatosplenomegaly         Anemia, thrombopenia, hypertriglycemia                               Autoimmune hemolytic anemia     2009
  Shukla et al. [28](#ccr31172-bib-0028){ref-type="ref"}                 23                        10                     No                                                                 No                                                                      Fever, hepatosplenomegaly         Pancytopenia, hypertriglycemia, hyperferritinemia                    Unclear                         2011
  Arewa et al. [16](#ccr31172-bib-0016){ref-type="ref"}                  21                        31                     No                                                                 No                                                                      Fever, jaundice, abdominal pain   Pancytopenia                                                         HIV                             2011
  Hannebicque Montaigne et al. [5](#ccr31172-bib-0005){ref-type="ref"}   29                        21                     Mixed connectivitis (lupus, cryoglobulinemia, Gougerot--Sjogren)   ICU transfer at 22 GA due to vascular failure, bilateral PE, at 25 GA   Fever                             Pancytopenia, hyperferritinemia, hypertriglycemia                    Lupus                           2012
  Dunn et al. [14](#ccr31172-bib-0014){ref-type="ref"}                   19                        41                     Still disease                                                      No                                                                      Fever, skin lesions               Cytolysis, anemia, leukopenia, hypertriglycemia, hyperferritinemia   Still Disease                   2012
  Mayama et al. [19](#ccr31172-bib-0019){ref-type="ref"}                 21                        28                     No                                                                 No                                                                      Fever                             Pancytopenia hyperferritinemia                                       Parvovirus B 19                 2014
  Tumian et al. [15](#ccr31172-bib-0015){ref-type="ref"}                 38                        35                     No                                                                 No                                                                      Jaundice                          Anemia, thrombopenia, hypertriglycemia, cytolysis                    CMV (postmortem diagnosis)      2015
  Samra et al. [18](#ccr31172-bib-0018){ref-type="ref"}                  16                        36                     No                                                                 No                                                                      Fever, hepatosplenomegaly         Pancytopenia, hyperferritinemia                                      Unclear                         2015
  Current                                                                30                        44                     Raynaud syndrome                                                   Autoimmune                                                              Fever, hepatomegaly               Pancytopenia, hyperferritinemia et hypertriglycemia, cytolysis       History of autoimmune disease   2015

ND, Not documented; IUGR, intrauterine growth retardation; DIVC, disseminated intravascular coagulation; PE, pulmonary embolism; GA, gestational age; CMV, cytomegalovirus; HSV, herpes simplex virus; HIV, human immunodeficiency virus; ICU, intensive care unit; EBV, Epstein--Barr virus.
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###### 

Displays the results of the comparison between our case and the related literature (second part)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors/\[biblio\]                                                     Prepartum treatments                                            Mortality risk factors                      C‐section yes/no              Neonatal gestational age (weeks)   Neonatal outcome                                                                     Maternal outcome                         Study year
  ---------------------------------------------------------------------- --------------------------------------------------------------- ------------------------------------------- ----------------------------- ---------------------------------- ------------------------------------------------------------------------------------ ---------------------------------------- ------------
  Gill et al. [11](#ccr31172-bib-0011){ref-type="ref"}                   Ig IV                                                           Anemia + thrombopenia                       No                            Full‐term                          Alive                                                                                Alive                                    1994

  Mihara et al. [10](#ccr31172-bib-0010){ref-type="ref"}                 Glucocorticoides, Ig IV, aciclovir, gabexate                    DIVC, age \>30                              No                            35                                 Alive                                                                                Alive                                    1999

  Nakabayashi et al. [13](#ccr31172-bib-0013){ref-type="ref"}            IgIV                                                            Preeclampsia, DIVC                          Yes                           29                                 Alive (respiratory distress)                                                         Alive                                    1999

  Chmait et al. [9](#ccr31172-bib-0009){ref-type="ref"}                  Ig IV, Aciclovir                                                DIVC                                        Yes                           30                                 Alive                                                                                Dead\                                    2000
                                                                                                                                                                                                                                                                                                                                           multi‐organ failure                      

  Yamagushi et al. [17](#ccr31172-bib-0017){ref-type="ref"}              Glucocorticoides, cyclosporine, aciclovir                       Hyperferritinemia                           Yes (breech presentation)     37                                 Alive                                                                                Alive                                    2005

  Pérard et al. [12](#ccr31172-bib-0012){ref-type="ref"}                 Glucocorticoides, IgIV                                          Anemia + thrombopenia + hyperferritinemia   No                            30                                 Alive                                                                                Alive (postpartum cerebral hemorrhage)   2007

  Hahaoka et al. [27](#ccr31172-bib-0027){ref-type="ref"}                Chemotherapy R‐CHOP, Cell transplantation                       Age \>30, anemia + thrombopenia             Yes                           28 (fetal distress)                Alive                                                                                Alive                                    2007

  Teng et al. [8](#ccr31172-bib-0008){ref-type="ref"}                    Glucocorticoides (treatment failure, improvement after birth)   Anemia + thrombopenia                       Yes                           29                                 Dead (respiratory distress)                                                          Alive                                    2009

  Shukla et al. [28](#ccr31172-bib-0028){ref-type="ref"}                 Glucocorticoides, abortion                                      Anemia + thrombopenia, hyperferritinemia    No                            10                                 Spontaneous miscarriage                                                              Alive                                    2011

  Arewa et al. [16](#ccr31172-bib-0016){ref-type="ref"}                  Antimalaria, HAART                                              Age \>30, anemia + thrombopenia             No                            Full‐term                          Alive                                                                                Alive                                    2011

  Hannebicque Montaigne et al. [5](#ccr31172-bib-0005){ref-type="ref"}   Ig IV, glucocorticoides                                         Anemia + thrombopenia + hyperferritinemia   No                            38                                 Alive (neuro postnatal follow‐up, MRI visible cerebral anoxia (asphyxial stigmata)   Alive                                    2012

  Dunn et al. [14](#ccr31172-bib-0014){ref-type="ref"}                   Glucocorticoides                                                Age \>30                                    Yes (IUGR + twin pregnancy)   30                                 Alive                                                                                Alive                                    2012

  Mayama et al. [19](#ccr31172-bib-0019){ref-type="ref"}                 Glucocorticoides                                                Hyperferritinemia                           No                            38                                 Alive                                                                                Alive                                    2014

  Tumian et al. [15](#ccr31172-bib-0015){ref-type="ref"}                 Postpartum onset: glucocorticoides\                             Age \>30, DIVC, retard diagnostic           Yes (fetal distress)          38                                 Alive                                                                                Dead multi‐organ failure                 2015
                                                                         IgIV, cyclosporine                                                                                                                                                                                                                                                                                         

  Samra et al. [18](#ccr31172-bib-0018){ref-type="ref"}                  Glucocorticoides                                                Age \>30, hyperferritinemia                 No                            Full‐term                          Alive                                                                                Alive                                    2015

  Current                                                                Antibiotherapies\                                               Age \>30, hyperferritinemia                 No                            38                                 Alive                                                                                Alive                                    2015
                                                                         glucocorticoides                                                                                                                                                                                                                                                                                           
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

IUGR, intrauterine growth retardation; DIVC, disseminated intravascular coagulation; Ig IV, immunoglobulin intravenous; HAART, highly active antiretroviral therapy.
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HPS diagnosis: clinical and biological symptoms {#ccr31172-sec-0004}
-----------------------------------------------

Hemophagocytic syndrome diagnosis was carried out taking into account several specific clinical signs, such as fever \>38.5°C, splenomegaly, hepatomegaly, lymphadenopathy, pulmonary infiltrates, erythema, purpura, and neurological evidence. Biological abnormalities were pancytopenia, cholestasis and cytolysis, hyperferritinemia, hypertriglyceridemia, hypofibrinogenemia, and increased LDH [4](#ccr31172-bib-0004){ref-type="ref"}, [7](#ccr31172-bib-0007){ref-type="ref"}, [20](#ccr31172-bib-0020){ref-type="ref"}, [21](#ccr31172-bib-0021){ref-type="ref"}. According to the literature, fever is the most prevalent clinical sign conveying patient to seek medical help, that is, the fever is often associated with pancytopenia and cytolysis [10](#ccr31172-bib-0010){ref-type="ref"} (Tables [2](#ccr31172-tbl-0002){ref-type="table-wrap"} and [3](#ccr31172-tbl-0003){ref-type="table-wrap"}).

HPS diagnostic tools {#ccr31172-sec-0005}
--------------------

Gold standard diagnostic tool is myelogram which allows identification of hemophagocytosis. Our patient\'s myelogram showed rich, infiltrated, and benign histiocyte--macrophages. In the absence of histological evidence, a repeated myelogram should be performed [22](#ccr31172-bib-0022){ref-type="ref"}.

Of note, hemophagocytosis is common in cases of polytransfusion or hematologic diseases and is not regarded as a pathognomonic criterion of HPS [23](#ccr31172-bib-0023){ref-type="ref"}.

HPS etiology {#ccr31172-sec-0006}
------------

Etiological evaluation led to ruling out anyneoplasia [6](#ccr31172-bib-0006){ref-type="ref"}, [7](#ccr31172-bib-0007){ref-type="ref"} (solid malignant tumors, hematologic malignancy). Upon patient questioning, no deterioration of general state was reported. Clinical examination did not reveal any mass or poly lymphadenopathy syndrome. In addition, the myelogram and blood workup did not reveal neoplastic malignant cells. Given the patient\'s medical history, HPS secondary to autoimmune disease seemed highly likely after excluding any infectious disease. Immune deficiency‐related HPS is very common [4](#ccr31172-bib-0004){ref-type="ref"}, [6](#ccr31172-bib-0006){ref-type="ref"}, [15](#ccr31172-bib-0015){ref-type="ref"}, [16](#ccr31172-bib-0016){ref-type="ref"}, [17](#ccr31172-bib-0017){ref-type="ref"}, [18](#ccr31172-bib-0018){ref-type="ref"}, [19](#ccr31172-bib-0019){ref-type="ref"} (45%). The most prevalent pathogens responsible for immune deficiency‐related HPS were reported to be herpesviridae, in particular, CMV, EBV, and HSV. Other less prevalent pathogens were mycobacteria and parasites. Advanced stages of HPS are reported to be secondary to HIV infection [16](#ccr31172-bib-0016){ref-type="ref"}, [24](#ccr31172-bib-0024){ref-type="ref"}. In immune deficiency‐related HPS, there is a challenge distinguishing the symptoms induced by pathogens from those secondary to immunosuppression. Indeed, most cases of secondary HPS have been reported in chronic immunosuppression, that is, patients with renal failure, HIV, hematologic or autoimmune disease. Immune deficiency‐related HPS was ruled out given the negative infectious workup.

HPS treatments {#ccr31172-sec-0007}
--------------

According to the literature, autoimmune related HPS can be treated by the following therapies: GC, intravenous immunoglobulins, methotrexate, and biotherapies [11](#ccr31172-bib-0011){ref-type="ref"}, [25](#ccr31172-bib-0025){ref-type="ref"}, [26](#ccr31172-bib-0026){ref-type="ref"}. The use of GC in our patient allowed reduction in disease progression and complications. Disease progression and its related complications were reduced after GC therapy.

HPS prognosis {#ccr31172-sec-0008}
-------------

Hemophagocytic syndrome prognosis was positive with satisfactory outcomes for the mother and the fetus. In case of autoimmune disease, the literature has reported only a few cases of positive pregnancy outcomes [10](#ccr31172-bib-0010){ref-type="ref"}, [13](#ccr31172-bib-0013){ref-type="ref"}, [16](#ccr31172-bib-0016){ref-type="ref"}. Fatal pregnancy outcomes have been reported across several reports [8](#ccr31172-bib-0008){ref-type="ref"}, [9](#ccr31172-bib-0009){ref-type="ref"}, [15](#ccr31172-bib-0015){ref-type="ref"}.

Discussion {#ccr31172-sec-0009}
==========

HPS diagnosis {#ccr31172-sec-0010}
-------------

Hemophagocytic syndrome diagnosis is challenging given its rare but serious characteristics often requiring intensive care. The median age for HPS occurrence is 48 yo \[35--62 yo\] [20](#ccr31172-bib-0020){ref-type="ref"} with male predominance [7](#ccr31172-bib-0007){ref-type="ref"}, [20](#ccr31172-bib-0020){ref-type="ref"}. There have only been a few reported cases of HPS during pregnancy with sometimes fatal fetal and maternal outcomes [5](#ccr31172-bib-0005){ref-type="ref"}, [8](#ccr31172-bib-0008){ref-type="ref"}, [9](#ccr31172-bib-0009){ref-type="ref"}, [10](#ccr31172-bib-0010){ref-type="ref"}, [11](#ccr31172-bib-0011){ref-type="ref"}, [12](#ccr31172-bib-0012){ref-type="ref"}, [13](#ccr31172-bib-0013){ref-type="ref"}, [14](#ccr31172-bib-0014){ref-type="ref"}, [15](#ccr31172-bib-0015){ref-type="ref"}, [16](#ccr31172-bib-0016){ref-type="ref"}, [17](#ccr31172-bib-0017){ref-type="ref"}, [18](#ccr31172-bib-0018){ref-type="ref"}, [19](#ccr31172-bib-0019){ref-type="ref"}. According to the literature, the mean age for HPS onset during pregnancy is 31 yo and diagnosis is carried out at the second trimester (around 22 GA) [8](#ccr31172-bib-0008){ref-type="ref"}, [12](#ccr31172-bib-0012){ref-type="ref"}, [13](#ccr31172-bib-0013){ref-type="ref"}, [16](#ccr31172-bib-0016){ref-type="ref"}, [17](#ccr31172-bib-0017){ref-type="ref"}, [19](#ccr31172-bib-0019){ref-type="ref"}, [27](#ccr31172-bib-0027){ref-type="ref"}, [28](#ccr31172-bib-0028){ref-type="ref"}.

HPS etiology {#ccr31172-sec-0011}
------------

According to the literature, autoimmune disease‐related HPS prevalence is around 7.2% [6](#ccr31172-bib-0006){ref-type="ref"}, [12](#ccr31172-bib-0012){ref-type="ref"}. Systemic diseases such as lupus (a prevalence of 2.4%, Wong et al. [29](#ccr31172-bib-0029){ref-type="ref"}) or Still\'s disease are the most prevalent cases of secondary HPS [6](#ccr31172-bib-0006){ref-type="ref"}, [7](#ccr31172-bib-0007){ref-type="ref"}, [29](#ccr31172-bib-0029){ref-type="ref"}, [30](#ccr31172-bib-0030){ref-type="ref"}. In prepartum, our patient presented with moderate peripheral autoimmune thrombocytopenia accompanied by antiribonucleoprotein antibodies and Raynaud\'s syndrome. In the absence of other events, no specific treatment was started. Nevertheless, the association of the above symptoms with the hormonal changes induced by pregnancy raised the question of vascular‐placental risk. Thus, acetyl salicylate DL‐lysine was prescribed during the entire pregnancy.

Fardet et al. [31](#ccr31172-bib-0031){ref-type="ref"} developed a diagnostic score for the adult HPS. It consists of several items: autoimmune disease, maximum temperature, hepatomegaly, splenomegaly, levels of hemoglobin, platelets and leukocytes levels, hyperferritinemia, hypertriglyceridemia, levels of fibrinogen and transaminase, hemophagocytosis found on the bone marrow. This score is a diagnostic aid for gynecologist--obstetrician facing an uncommon but serious pathology often underdiagnosed. It is accessible on <http://saintantoine.aphp.fr/score/>. According to this score, there was a 96.7% probability that our patient had HPS.

HPS and pregnancy‐induced risk factors {#ccr31172-sec-0012}
--------------------------------------

Pregnancy is a time when the immune system is strongly stimulated and the placenta plays the role of immunological barrier between the fetus and the mother [28](#ccr31172-bib-0028){ref-type="ref"}. However, this mechanism fails in pregnancy pathologies such as preeclampsia. Given the variable immunological disturbances during pregnancy, it becomes a favorable context to trigger HPS in the presence of additional risk factors such as systemic disease or infection [20](#ccr31172-bib-0020){ref-type="ref"}. To date, there is no literature on oocyte donation and recipient mother\'s immune conflict. Nevertheless, we did set forth such likely correlation, that is, the recipient\'s immunological reaction seemed to be triggered against the presence of unknown genetic matter. Several studies have highlighted an increased rate of pregnancy‐induced hypertension and preeclampsia in patients who underwent in vitro fertilization by oocyte donation versus oocytes of the recipient (OR = 3.3; 95% CI \[1.2--8.9\]) [32](#ccr31172-bib-0032){ref-type="ref"}, [33](#ccr31172-bib-0033){ref-type="ref"}, [34](#ccr31172-bib-0034){ref-type="ref"}. We believe that this higher pregnancy‐induced hypertension and preeclampsia can be explained by the recipient\'s immunological reaction triggered against the presence of unknown genetic matter, that is, allogeneic graft. Triggered immunological mechanism of the mother impairs placental implantation and increases maternal systemic resistance leading to preeclampsia and further complications of autoimmune reaction [35](#ccr31172-bib-0035){ref-type="ref"}. During pregnancy, in the presence of numerous biological signs similar to those of HPS, clinicians should first preclude a differential diagnosis of preeclampsia. Preeclampsia was excluded in our patient case.

HPS prognosis {#ccr31172-sec-0013}
-------------

Mortality rate linked to the primary or secondary HPS is very high. In HPS, prognosis is poor in 49% of cases and patients with HIV or malignant hemopathy are at higher risk of mortality [6](#ccr31172-bib-0006){ref-type="ref"}, [7](#ccr31172-bib-0007){ref-type="ref"}. The literature has put forward the mean premature GA of 30 weeks [7](#ccr31172-bib-0007){ref-type="ref"}, [11](#ccr31172-bib-0011){ref-type="ref"}, requiring most likely a C‐section for fetal and maternal salvage in cases of preeclampsia or cerebral hemorrhage [9](#ccr31172-bib-0009){ref-type="ref"}, [12](#ccr31172-bib-0012){ref-type="ref"}, [13](#ccr31172-bib-0013){ref-type="ref"}, [14](#ccr31172-bib-0014){ref-type="ref"}, [15](#ccr31172-bib-0015){ref-type="ref"}, [17](#ccr31172-bib-0017){ref-type="ref"}. Kaito et al. identified the following risk factors of mortality: maternal age \>30 years, intravascular disseminated coagulation, anemia associated with thrombocytopenia, cholestasis, elevated ferritin, and β2 microglobulinemia [36](#ccr31172-bib-0036){ref-type="ref"}.

HPS treatment {#ccr31172-sec-0014}
-------------

To date, there is no consensus on the best management of either primary or secondary HPS. The overall aim of treatment is to resolve all hydroelectric disorders, transfuse in case of cytopenia, and manage organ failures [37](#ccr31172-bib-0037){ref-type="ref"}. In addition, it is necessary to treat the cause of HPS: antimicrobial treatment, chemotherapy, or immunomodulators. GC have played a major role in treatment of HPS between 1994 and 2004 and this regardless of the underlying etiology [18](#ccr31172-bib-0018){ref-type="ref"}.

Even though immunoglobulins are being regarded as the first‐line treatments for HPS, GC have been used as the first‐line treatments in most reported cases [8](#ccr31172-bib-0008){ref-type="ref"}, [11](#ccr31172-bib-0011){ref-type="ref"}, [16](#ccr31172-bib-0016){ref-type="ref"}, [19](#ccr31172-bib-0019){ref-type="ref"}. Immunoglobulins and cyclosporine have been mostly used for HPS treatment in GC‐resistant cases [18](#ccr31172-bib-0018){ref-type="ref"}.

Conclusion {#ccr31172-sec-0015}
==========

Hemophagocytic syndrome is not well known during pregnancy, yet can be fatal. Mother\'s and fetus\'s prognoses are poor and require vital emergency care. HPS diagnosis is a challenge due to variable clinical presentation and nonspecificity of the clinical and biological findings. Mortality, prognosis, and disease progression may be influenced by delay in diagnosis, treatment onset, and HPS etiology. This case and its comparison to the literature showed the absence of consensual diagnosis and management of HPS. Making the right diagnosis in a timely manner during pregnancy seems to be the most significant barrier to treatment and would offer the best prognosis for the patient. Multidisciplinary team work is mandatory to reach prompt diagnosis for such uncommon yet fatal disorder during pregnancy. Clinicians should be alerted when there is an association of clinical and biological signs such as fever, pancytopenia, hyperferritinemia, and hypertriglycemia to suspect HPS and proceed with prompt treatments. To reach consensus on diagnostic criteria for HPS, diagnostic scoring tools, for example, Fardet et al. [31](#ccr31172-bib-0031){ref-type="ref"} scoring, as well as novel therapies such as immune modulators combined with biotherapies should be taken into account in further observational studies.
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